KPRXHIGH SIGNALFINANCIAL10-K

KPRX shows concerning financial deterioration with total assets declining by one-third while R&D expenses increased substantially, indicating potential cash burn acceleration.

The company's balance sheet contracted significantly across all major categories, with stockholders' equity falling 37% to $16.1M, suggesting substantial cash consumption during the period. The simultaneous increase in R&D spending to $10.8M while assets shrink indicates an unsustainable burn rate that could threaten the company's ability to fund operations without additional capital raises.

Comparing 2026-03-25 vs 2025-03-25View on EDGAR →
FINANCIAL ANALYSIS

KPRX experienced broad-based balance sheet contraction with total assets declining 34% to $24.3M and stockholders' equity falling to $16.1M. While liabilities also decreased, the company simultaneously increased R&D spending by 38% to $10.8M, creating a concerning mismatch between resource consumption and available capital. The combination of shrinking assets and rising operational expenses suggests accelerating cash burn that warrants close monitoring of the company's liquidity position.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-39.6%
$6.0M$3.6M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
+37.5%
$7.8M$10.8M

R&D investment increased 37.5% — signals commitment to future product development, though near-term margin impact.

Stockholders Equity
Balance Sheet
-37.4%
$25.8M$16.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Assets
Balance Sheet
-33.5%
$36.5M$24.3M

Total assets contracted 33.5% — asset sales, write-downs, or balance sheet optimization underway.

Interest Expense
P&L
+29.5%
$9K$11K

Interest costs rose 29.5% — monitor debt levels and coverage ratio in rising rate environment.

Current Assets
Balance Sheet
-26.8%
$29.7M$21.7M

Current assets declined 26.8% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-24.2%
$10.7M$8.1M

Liabilities reduced 24.2% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-25
PRIOR — 2025-03-25
ADDED
At March 21, 2026, there were 3,950,628 shares of the registrant s common stock outstanding.
Risk Factors beginning on page of 21 this Annual Report on Form 10-K.
You should carefully review all of these factors, as well as other risks described in our public filings.
Except as required by federal securities laws, we undertake no obligation to update these forward-looking statements to disclose material developments related to previously disclosed information.
We completed a Phase 1b clinical trial in September 2023 and presented topline results in November 2023 at the American Academy of Ophthalmology Annual Meeting.
+7 more — sign up free →
REMOVED
At March 21, 2025, there were 3,000,788 shares of the registrant s common stock outstanding.
We discuss many of these risks in detail under the heading Item 1A.
Risk Factors beginning on page of 17 this Annual Report on Form 10-K.
You should carefully review all of these factors, as well as other risks described in our public filings, and you should be aware that there may be other factors, including factors of which we are not currently aware, that could cause these differences.
We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →